 |
|
JAMA-EXPRESS
Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States
Rick A. Bright, PhD;
David K. Shay, MD, MPH;
Bo Shu, MD;
Nancy J. Cox, PhD;
Alexander I. Klimov, PhD
JAMA. 2006;295:891-894. Published online February 2, 2006 (doi:10.1001/jama.295.8.joc60020).
Context The adamantanes, amantadine and rimantadine, have been used as first-choice antiviral drugs against community outbreaks of influenza A viruses for many years. Rates of viruses resistant to these drugs have been increasing globally. Rapid surveillance for the emergence and spread of resistant viruses has become critical for appropriate treatment of patients.
Objective To investigate the frequency of adamantane-resistant influenza A viruses circulating in the United States during the initial months of the 2005-2006 influenza season.
Design and Setting Influenza isolates collected from 26 states from October 1 through December 31, 2005, and submitted to the US Centers for Disease Control and Prevention were tested for drug resistance as part of ongoing surveillance. Isolates were submitted from World Health Organization collaborating laboratories and National Respiratory and Enteric Virus Surveillance System laboratories.
Main Outcome Measures Using pyrosequencing and confirmatory assays, we identified viruses containing mutations within the M2 gene that are known to confer resistance to both amantadine and rimantadine.
Results A total of 209 influenza A(H3N2) viruses isolated from patients in 26 states were screened, of which 193 (92.3%) contained a change at amino acid 31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same mutation. Drug-resistant viruses were distributed across the United States.
Conclusions The high proportion of influenza A viruses currently circulating in the United States demonstrating adamantane resistance highlights the clinical importance of rapid surveillance for antiviral resistance. Our results indicate that these drugs should not be used for the treatment or prophylaxis of influenza in the United States until susceptibility to adamantanes has been reestablished among circulating influenza A isolates.
Author Affiliations: Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Influenza Branch, Atlanta, Ga. As of February 1, 2006, Dr Bright is with Novavax, Malvern, Pa.
RELATED LETTERS
Shift Shown in Influenza A Adamantane Resistance
Katherine M. Shea
JAMA. 2006;296(13):1585.
EXTRACT
| FULL TEXT
Shift Shown in Influenza A Adamantane Resistance
Raj C. Shah
JAMA. 2006;296(13):1585-1586.
EXTRACT
| FULL TEXT
Shift Shown in Influenza A Adamantane Resistance—Reply
David K. Shay, Rick A. Bright, Michael Shaw, Nancy J. Cox, and Alexander I. Klimov
JAMA. 2006;296(13):1586-1587.
EXTRACT
| FULL TEXT
Shift Shown in Influenza A Adamantane Resistance—Reply
David M. Weinstock and Gianna Zucotti
JAMA. 2006;296(13):1587.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Adamantane Resistance in Influenza A
David M. Weinstock and Gianna Zuccotti
JAMA. 2006;295(8):934-936.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008
Sheu et al.
Antimicrob. Agents Chemother. 2008;52:3284-3292.
ABSTRACT
| FULL TEXT
Genetic Analysis of Influenza A/H3N2 and A/H1N1 Viruses Circulating in Vietnam from 2001 to 2006
Li et al.
J. Clin. Microbiol. 2008;46:399-405.
ABSTRACT
| FULL TEXT
The Genesis and Spread of Reassortment Human Influenza A/H3N2 Viruses Conferring Adamantane Resistance
Simonsen et al.
Mol Biol Evol 2007;24:1811-1820.
ABSTRACT
| FULL TEXT
Avian Influenza Virus (H5N1): a Threat to Human Health
Peiris et al.
Clin. Microbiol. Rev. 2007;20:243-267.
ABSTRACT
| FULL TEXT
Antiviral Therapy and Prophylaxis for Influenza in Children
Committee on Infectious Diseases
Pediatrics 2007;119:852-860.
ABSTRACT
| FULL TEXT
Amantadine-Resistant Influenza A (H3N2) Virus in Japan, 2005-2006
Saito et al.
NEJM 2007;356:312-313.
FULL TEXT
Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells
Jones et al.
J. Virol. 2006;80:11960-11967.
ABSTRACT
| FULL TEXT
Update: Influenza Activity--United States and Worldwide, May 21-September 9, 2006
JAMA 2006;296:2549-2550.
FULL TEXT
Shift Shown in Influenza A Adamantane Resistance
Shea
JAMA 2006;296:1585-1585.
FULL TEXT
Shift Shown in Influenza A Adamantane Resistance
Shah
JAMA 2006;296:1585-1586.
FULL TEXT
Longitudinal analysis of genotype distribution of influenza a virus from 2003 to 2005.
Mak et al.
J. Clin. Microbiol. 2006;44:3583-3588.
ABSTRACT
| FULL TEXT
High Adamantane Resistance in Influenza A Isolates
JWatch Emergency Med. 2006;2006:20-20.
FULL TEXT
Emergence of drug-resistant influenza virus: population dynamical considerations.
Regoes and Bonhoeffer
Science 2006;312:389-391.
ABSTRACT
| FULL TEXT
Influenza A Resistance to Adamantanes
JWatch Gastroenterology 2006;2006:11-11.
FULL TEXT
What's new in the other general journals.
Tonks
BMJ 2006;332:536-537.
FULL TEXT
Influenza A Resistance to Adamantane
JWatch General 2006;2006:5-5.
FULL TEXT
Adamantane Resistance in Influenza A
Weinstock and Zuccotti
JAMA 2006;295:934-936.
FULL TEXT
|
